Aerie Pharmaceuticals, Inc. (AERI) to Release Earnings on Tuesday
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) is scheduled to be posting its quarterly earnings results after the market closes on Tuesday, August 1st. Analysts expect Aerie Pharmaceuticals to post earnings of ($0.62) per share for the quarter.
Aerie Pharmaceuticals (NASDAQ:AERI) last issued its earnings results on Tuesday, May 2nd. The company reported ($0.76) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.74) by $0.02. On average, analysts expect Aerie Pharmaceuticals to post $-3.13 EPS for the current fiscal year and $-2.6 EPS for the next fiscal year.
Shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) opened at 57.60 on Tuesday. The stock has a 50 day moving average of $53.99 and a 200-day moving average of $46.83. Aerie Pharmaceuticals, Inc. has a 12 month low of $16.61 and a 12 month high of $59.50. The firm’s market capitalization is $1.94 billion.
Several equities research analysts recently commented on the stock. JMP Securities reiterated an “outperform” rating and issued a $57.00 price objective on shares of Aerie Pharmaceuticals in a research report on Friday, March 31st. Stifel Nicolaus boosted their price objective on shares of Aerie Pharmaceuticals from $55.00 to $65.00 and gave the stock a “buy” rating in a research report on Thursday, April 6th. Aegis reiterated a “buy” rating and issued a $63.00 price objective on shares of Aerie Pharmaceuticals in a research report on Thursday, April 13th. Cantor Fitzgerald set a $56.00 price objective on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, April 12th. Finally, HC Wainwright set a $69.00 price objective on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, April 15th. One analyst has rated the stock with a sell rating, two have given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Aerie Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $65.69.
ILLEGAL ACTIVITY NOTICE: This report was first posted by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2017/07/25/aerie-pharmaceuticals-inc-aeri-to-release-earnings-on-tuesday.html.
In related news, major shareholder Foresite Capital Fund Ii, L.P. sold 20,000 shares of the business’s stock in a transaction dated Friday, May 26th. The shares were sold at an average price of $55.95, for a total value of $1,119,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 9.36% of the company’s stock.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.